In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD)

Psychopharmacology

Volumn 228, Issue 4, 2013, Pages 633-640

  Haghighi, Mohammad ^a   Jahangard, Leila ^a   Mohammad Beigi, Hamid ^b   Bajoghli, Hafez ^c   Hafezian, Hassan ^a   Rahimi, Alireza ^a   Afshar, Hamid ^b   Holsboer Trachsler, Edith ^d   Brand, Serge ^d  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Double blind trial; Memantine; Obsessive compulsive disorder; Placebo; SSRIs; Y BOCS

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; MEMANTINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONFUSION; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; FEMALE; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; MALE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SIDE EFFECT; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; VERTIGO; VOMITING; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ADULT; CLOMIPRAMINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; MEMANTINE; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84881219396     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3067-z     Document Type: Article

References (40)

1. Ackerman DL, Greenland S (2002) Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol 22:309-317
2. Afshar H, Roohafza H, Mohammad-Beigi H, Haghighi M, Jahangard L, Shokouh P, Sadeghi M, Hafezian H (2012) N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 32:797-803
3. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DC
4. Bhattacharyya S, Khanna S, Chakrabarty K, Mahadevan A, Christopher R, Shankar SK (2009) Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder. Neuropsychopharmacology 34:2489-2496
5. Carlsson ML (2001) On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 25:5-26
6. Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S (2001) Glutamatergic dysfunction in OCD. Neuropsychopharmacology 30:1735-1740
7. Cohen J (1988) Statistical power analysis for the behavioural sciences, 2nd edn. Lawrence Erlbaum Associates, Hillsdale
8. Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, Huppert JD, Kjernisted K, Rowan V, Schmidt AB, Simpson HB, Tu X (2005) Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 162:151-161
9. Franklin ME, Foa EB (2011) Treatment of obsessive compulsive disorder. Annu Rev Clin Psychol 7:229-243
10. Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S (2013) Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res 47:175-180
11. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS (1989) The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 46:1012-1016
12. Goodman WK, Kozak MJ, Liebowitz M, White KL (1996) Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 11:21-29
13. Guy W (1976) ECDEU assessment for psychopharmacology, revised edition. NIMH Publication, Rockville
14. Hanna GL, Himle JA, Curtis GC, Gillespie BW (2005) A family study of obsessive-compulsive disorder with pediatric probands. Am J Med Genet B Neuropsychiatr Genet 134:13-19
15. Hettema JM, Neale MC, Kendler KS (2001) A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 158:1568-1578
16. Hezel DM, Beattie K, Stewart SE (2009) Memantine as an augmenting agent for severe pediatric OCD. Am J Psychiatry 166:237
17. Hollander E (1996) Obsessive-compulsive disorder-related disorders: the role of selective serotonergic reuptake inhibitors. Int Clin Psychopharmacol 11(suppl 5):75-87
18. Joint Formulary Committee (2004) British National Formulary (BNF), 47th edn. British Medical Association and the Royal Pharmaceutical Society of Great Britain, London
19. Karno M, Golding JM, Sorenson SB, Burnam MA (1988) The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 45:1094-1099
20. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602
21. Mataix-Cols D, Rauch SL, Baer L, Eisen JL, Shera DM, Goodman WK, Rasmussen SA, Jenike MA (2002) Symptom stability in adult obsessive-compulsive disorder: data from a naturalistic two-year follow-up study. Am J Psychiatry 159:263-268
22. McGrath MJ, Campbell KM, Parks CR, Burton FH (2000) Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder. Brain Res 877:23-30
23. Pallanti S, Quercioli L (2006) Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry 30:400-412
24. Pasquini M, Biondi M (2006) Memantine augmentation for refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 30:1173-1175
25. Pigott TA, Seay SM (1999) A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 60:101-106
26. Poyurovsky M, Weizman R, Weizman A, Koran L (2005) Memantine for treatment-resistant OCD. Am J Psychiatry 162:2191-2192
27. Rosenberg DR, Keshavan MS (1998) A.E. Bennett Research Award. Toward a neurodevelopmental model of obsessive-compulsive disorder. Biol Psychiatry 43:623-640
28. Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ (2000) Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 39:1096-1103
29. Rosenberg DR, Mirza Y, Russell A, Tang J, Smith JM, Banerjee SP, Bhandari R, Rose M, Ivey J, Boyd C, Moore GJ (2004) Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry 43:1146-1153
30. Ruscio AM, Stein DJ, Chiu WT, Kessler RC (2010) The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 15:53-63
31. Saxena S, Rauch SL (2000) Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatr Clin North Am 23:563-586
32. Saxena S, Bota RG, Brody AL (2001) Brain-behavior relationships in obsessive-compulsive disorder. Semin Clin Neuropsychiatry 6:82-101
33. Starck G, Ljungberg M, Nilsson M, Jönsson L, Lundberg S, Ivarsson T, Ribbelin S, Ekholm S, Carlsson A, Forssell-Aronsson E, Carlsson ML (2008) A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity. J Neural Transm 115:1051-1062
34. Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L, Jenike MA (2010) A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol 30:34-39
35. Swedo SE, Snider LA (2004) The neurobiology and treatment of obsessive compulsive disorder. In: Nestler EJ, Charney DS (eds) Neurobiology of mental illness. Oxford University Press, New York, pp 628-638
36. Ting JT, Feng G (2011) Neurobiology of obsessive-compulsive disorder: insights into neural circuitry dysfunction through mouse genetics. Curr Opin Neurobiol 21:842-848
37. van Grootheest DS, Cath DC, Beekman AT, Boomsma DI (2005) Twin studies on obsessive-compulsive disorder: a review. Twin Res Hum Genet 8:450-458
38. Whiteside SP, Port JD, Deacon BJ, Abramowitz JS (2006) A magnetic resonance spectroscopy investigation of obsessive-compulsive disorder and anxiety. Psychiatry Res 146:137-147
39. Wu K, Hanna GL, Rosenberg DR, Arnold PD (2012) The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol Biochem Behav 100:726-735
40. Yücel M, Wood SJ, Wellard RM, Harrison BJ, Fornito A, Pujol J, Velakoulis D, Pantelis C (2008) Anterior cingulate glutamate-glutamine levels predict symptom severity in women with obsessive-compulsive disorder. Aust N Z J Psychiatry 42:467-477